-DOCSTART- -X- O
Despite -X- _ O
causing -X- _ O
pandemics -X- _ O
and -X- _ O
yearly -X- _ O
epidemics -X- _ O
that -X- _ O
result -X- _ O
in -X- _ O
significant -X- _ O
morbidity -X- _ O
and -X- _ O
mortality -X- _ O
, -X- _ O
our -X- _ O
arsenal -X- _ O
of -X- _ O
options -X- _ O
to -X- _ O
treat -X- _ O
influenza -X- _ B-Patient
A -X- _ I-Patient
virus -X- _ I-Patient
( -X- _ I-Patient
IAV -X- _ I-Patient
) -X- _ I-Patient
infections -X- _ I-Patient
remains -X- _ O
limited -X- _ O
and -X- _ O
is -X- _ O
challenged -X- _ O
by -X- _ O
the -X- _ O
virus -X- _ O
itself. -X- _ O
While -X- _ O
vaccination -X- _ O
is -X- _ O
the -X- _ O
preferred -X- _ O
intervention -X- _ O
strategy -X- _ O
against -X- _ O
influenza -X- _ O
, -X- _ O
its -X- _ O
efficacy -X- _ O
is -X- _ O
reduced -X- _ O
in -X- _ O
the -X- _ O
elderly -X- _ O
and -X- _ O
infants -X- _ O
who -X- _ O
are -X- _ O
most -X- _ O
susceptible -X- _ O
to -X- _ O
severe -X- _ O
and -X- _ O
/ -X- _ O
or -X- _ O
fatal -X- _ O
infections. -X- _ O
In -X- _ O
addition -X- _ O
, -X- _ O
antigenic -X- _ O
variation -X- _ O
of -X- _ O
IAV -X- _ O
complicates -X- _ O
the -X- _ O
production -X- _ O
of -X- _ O
efficacious -X- _ O
vaccines. -X- _ O
Similarly -X- _ O
, -X- _ O
effectiveness -X- _ O
of -X- _ O
currently -X- _ O
used -X- _ O
antiviral -X- _ O
drugs -X- _ O
is -X- _ O
jeopardized -X- _ O
by -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
resistance -X- _ O
to -X- _ O
these -X- _ O
drugs. -X- _ O
Like -X- _ O
many -X- _ O
viruses -X- _ O
, -X- _ O
IAV -X- _ O
is -X- _ O
reliant -X- _ O
on -X- _ O
host -X- _ O
factors -X- _ O
and -X- _ O
signaling-pathways -X- _ O
for -X- _ O
its -X- _ O
replication -X- _ O
, -X- _ O
which -X- _ O
could -X- _ O
potentially -X- _ O
offer -X- _ O
alternative -X- _ O
options -X- _ O
to -X- _ O
treat -X- _ O
infections. -X- _ O
While -X- _ O
host-factors -X- _ O
have -X- _ O
long -X- _ O
been -X- _ O
recognized -X- _ O
as -X- _ O
attractive -X- _ O
therapeutic -X- _ O
candidates -X- _ O
against -X- _ O
other -X- _ O
viruses -X- _ O
, -X- _ O
only -X- _ O
recently -X- _ O
they -X- _ O
have -X- _ O
been -X- _ O
targeted -X- _ O
for -X- _ O
development -X- _ O
as -X- _ O
IAV -X- _ O
antivirals. -X- _ O
Future -X- _ O
strategies -X- _ O
to -X- _ O
combat -X- _ O
IAV -X- _ O
infections -X- _ O
will -X- _ O
most -X- _ O
likely -X- _ O
include -X- _ O
approaches -X- _ O
that -X- _ O
alter -X- _ O
host-virus -X- _ O
interactions -X- _ O
on -X- _ O
the -X- _ O
one -X- _ O
hand -X- _ O
or -X- _ O
dampen -X- _ O
harmful -X- _ O
host -X- _ O
immune -X- _ O
responses -X- _ O
on -X- _ O
the -X- _ O
other -X- _ O
, -X- _ O
with -X- _ O
the -X- _ O
use -X- _ O
of -X- _ O
biological -X- _ O
response -X- _ O
modifiers -X- _ O
( -X- _ O
BRMs -X- _ O
) -X- _ O
. -X- _ O
In -X- _ O
principle -X- _ O
, -X- _ O
BRMs -X- _ B-Intervention
are -X- _ I-Intervention
biologically -X- _ I-Intervention
active -X- _ I-Intervention
agents -X- _ I-Intervention
including -X- _ I-Intervention
antibodies -X- _ I-Intervention
, -X- _ I-Intervention
small -X- _ I-Intervention
peptides -X- _ I-Intervention
, -X- _ I-Intervention
and -X- _ I-Intervention
/ -X- _ I-Intervention
or -X- _ I-Intervention
other -X- _ I-Intervention
( -X- _ I-Intervention
small -X- _ I-Intervention
) -X- _ I-Intervention
molecules -X- _ I-Intervention
that -X- _ I-Intervention
can -X- _ I-Intervention
influence -X- _ I-Intervention
the -X- _ I-Intervention
immune -X- _ I-Intervention
response. -X- _ I-Intervention
BRMs -X- _ O
are -X- _ O
already -X- _ O
being -X- _ O
used -X- _ O
in -X- _ O
the -X- _ O
clinic -X- _ O
to -X- _ O
treat -X- _ O
malignancies -X- _ O
and -X- _ O
autoimmune -X- _ O
diseases. -X- _ O
Repurposing -X- _ O
such -X- _ O
agents -X- _ O
would -X- _ O
allow -X- _ O
for -X- _ O
accelerated -X- _ O
use -X- _ O
against -X- _ O
severe -X- _ O
and -X- _ O
potentially -X- _ O
fatal -X- _ O
IAV -X- _ O
infections. -X- _ O
In -X- _ O
this -X- _ O
review -X- _ O
, -X- _ O
we -X- _ O
will -X- _ O
address -X- _ O
the -X- _ O
potential -X- _ O
therapeutic -X- _ O
use -X- _ O
of -X- _ O
different -X- _ O
BRM -X- _ O
classes -X- _ O
to -X- _ O
modulate -X- _ O
the -X- _ O
immune -X- _ O
response -X- _ O
induced -X- _ O
after -X- _ O
IAV -X- _ O
infections -X- _ O
. -X- _ O

